Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors

Edgardo Rivera, Joyce S Lee, Angela Davies

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Chemotherapy efficacy in patients with solid tumors is influenced by primary and acquired multidrug resistance (MDR). Epothilones represent a novel class of microtubule inhibitors with lower susceptibility to drug resistance and efficacy in taxane-resistant tumors. While other epothilones are currently under investigation, ixabepilone is the first epothilone B analogue approved by the U.S. Food and Drug Administration. Ixabepilone has been shown to have preclinical activity in chemotherapy-sensitive and chemotherapy-resistant tumor models, and synergistic antitumor activity with other chemotherapeutic and targeted agents. Single-agent ixabepilone has demonstrated clinical activity in multiple solid tumors including advanced breast, lung, prostate, pancreatic, renal cell, and ovarian cancers. Most notably, efficacy has been demonstrated in patients with metastatic breast cancer (MBC) progressing after treatment with anthracyclines and taxanes. A phase III trial in anthracycline-and taxane-resistant MBC showed superior disease control with ixabepilone plus capecitabine versus capecitabine monotherapy, resulting in its approval. Ixabepilone is also active in chemotherapy-naïve and taxane-resistant hormone-refractory prostate cancer and platinum-resistant non-small cell lung cancer. Neutropenia and peripheral sensory neuropathy are the most common adverse events associated with treatment. This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone.

Original languageEnglish (US)
Pages (from-to)1207-1223
Number of pages17
JournalOncologist
Volume13
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Epothilones
Drug Therapy
Neoplasms
Anthracyclines
Multiple Drug Resistance
Breast Neoplasms
Taxoids
Peripheral Nervous System Diseases
United States Food and Drug Administration
Neutropenia
Platinum
Renal Cell Carcinoma
Drug Resistance
Non-Small Cell Lung Carcinoma
Microtubules
Ovarian Neoplasms
ixabepilone
Prostate
Prostatic Neoplasms
Breast

Keywords

  • Breast cancer
  • Epothilones
  • Ixabepilone
  • Multidrug resistance
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. / Rivera, Edgardo; Lee, Joyce S; Davies, Angela.

In: Oncologist, Vol. 13, No. 12, 12.2008, p. 1207-1223.

Research output: Contribution to journalArticle

Rivera, Edgardo ; Lee, Joyce S ; Davies, Angela. / Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. In: Oncologist. 2008 ; Vol. 13, No. 12. pp. 1207-1223.
@article{677fe0b6c99047c38c576d0db1515a13,
title = "Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors",
abstract = "Chemotherapy efficacy in patients with solid tumors is influenced by primary and acquired multidrug resistance (MDR). Epothilones represent a novel class of microtubule inhibitors with lower susceptibility to drug resistance and efficacy in taxane-resistant tumors. While other epothilones are currently under investigation, ixabepilone is the first epothilone B analogue approved by the U.S. Food and Drug Administration. Ixabepilone has been shown to have preclinical activity in chemotherapy-sensitive and chemotherapy-resistant tumor models, and synergistic antitumor activity with other chemotherapeutic and targeted agents. Single-agent ixabepilone has demonstrated clinical activity in multiple solid tumors including advanced breast, lung, prostate, pancreatic, renal cell, and ovarian cancers. Most notably, efficacy has been demonstrated in patients with metastatic breast cancer (MBC) progressing after treatment with anthracyclines and taxanes. A phase III trial in anthracycline-and taxane-resistant MBC showed superior disease control with ixabepilone plus capecitabine versus capecitabine monotherapy, resulting in its approval. Ixabepilone is also active in chemotherapy-na{\"i}ve and taxane-resistant hormone-refractory prostate cancer and platinum-resistant non-small cell lung cancer. Neutropenia and peripheral sensory neuropathy are the most common adverse events associated with treatment. This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone.",
keywords = "Breast cancer, Epothilones, Ixabepilone, Multidrug resistance, Prostate cancer",
author = "Edgardo Rivera and Lee, {Joyce S} and Angela Davies",
year = "2008",
month = "12",
doi = "10.1634/theoncologist.2008-0143",
language = "English (US)",
volume = "13",
pages = "1207--1223",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "12",

}

TY - JOUR

T1 - Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors

AU - Rivera, Edgardo

AU - Lee, Joyce S

AU - Davies, Angela

PY - 2008/12

Y1 - 2008/12

N2 - Chemotherapy efficacy in patients with solid tumors is influenced by primary and acquired multidrug resistance (MDR). Epothilones represent a novel class of microtubule inhibitors with lower susceptibility to drug resistance and efficacy in taxane-resistant tumors. While other epothilones are currently under investigation, ixabepilone is the first epothilone B analogue approved by the U.S. Food and Drug Administration. Ixabepilone has been shown to have preclinical activity in chemotherapy-sensitive and chemotherapy-resistant tumor models, and synergistic antitumor activity with other chemotherapeutic and targeted agents. Single-agent ixabepilone has demonstrated clinical activity in multiple solid tumors including advanced breast, lung, prostate, pancreatic, renal cell, and ovarian cancers. Most notably, efficacy has been demonstrated in patients with metastatic breast cancer (MBC) progressing after treatment with anthracyclines and taxanes. A phase III trial in anthracycline-and taxane-resistant MBC showed superior disease control with ixabepilone plus capecitabine versus capecitabine monotherapy, resulting in its approval. Ixabepilone is also active in chemotherapy-naïve and taxane-resistant hormone-refractory prostate cancer and platinum-resistant non-small cell lung cancer. Neutropenia and peripheral sensory neuropathy are the most common adverse events associated with treatment. This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone.

AB - Chemotherapy efficacy in patients with solid tumors is influenced by primary and acquired multidrug resistance (MDR). Epothilones represent a novel class of microtubule inhibitors with lower susceptibility to drug resistance and efficacy in taxane-resistant tumors. While other epothilones are currently under investigation, ixabepilone is the first epothilone B analogue approved by the U.S. Food and Drug Administration. Ixabepilone has been shown to have preclinical activity in chemotherapy-sensitive and chemotherapy-resistant tumor models, and synergistic antitumor activity with other chemotherapeutic and targeted agents. Single-agent ixabepilone has demonstrated clinical activity in multiple solid tumors including advanced breast, lung, prostate, pancreatic, renal cell, and ovarian cancers. Most notably, efficacy has been demonstrated in patients with metastatic breast cancer (MBC) progressing after treatment with anthracyclines and taxanes. A phase III trial in anthracycline-and taxane-resistant MBC showed superior disease control with ixabepilone plus capecitabine versus capecitabine monotherapy, resulting in its approval. Ixabepilone is also active in chemotherapy-naïve and taxane-resistant hormone-refractory prostate cancer and platinum-resistant non-small cell lung cancer. Neutropenia and peripheral sensory neuropathy are the most common adverse events associated with treatment. This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone.

KW - Breast cancer

KW - Epothilones

KW - Ixabepilone

KW - Multidrug resistance

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=58749113261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749113261&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0143

DO - 10.1634/theoncologist.2008-0143

M3 - Article

C2 - 19088324

AN - SCOPUS:58749113261

VL - 13

SP - 1207

EP - 1223

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -